Ondrej Blaha, PhD
Associate Research Scientist in Biostatistics
Research & Publications
Biography
Locations
Coauthors
Selected Publications
- Perioperative Modified FOLFIRINOX for Resectable Pancreatic CancerCecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10 PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.
- A Bayesian platform trial design with hybrid control based on multisource exchangeability modellingWei W, Blaha O, Esserman D, Zelterman D, Kane M, Liu R, Lin J. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling. Statistics In Medicine 2024, 43: 2439-2451. PMID: 38594809, DOI: 10.1002/sim.10077.
- Abstract 1186: Moving beyond conventional autoimmune thyroiditis autoantibodies to predict immune checkpoint inhibitor induced hypothyroidismBlenman K, Blaha O, Gibson C, Qiu S, Rushmeier H, Ibrahim M, Qiu S, Krosgsgaard M, Osman I. Abstract 1186: Moving beyond conventional autoimmune thyroiditis autoantibodies to predict immune checkpoint inhibitor induced hypothyroidism. Cancer Research 2024, 84: 1186-1186. DOI: 10.1158/1538-7445.am2024-1186.
- Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 TrialShallis R, Blaha O, Halene S, Mendez L, Podoltsev N, Caldwell A, Bewersdorf J, Little R, Piekarz R, Patnaik M, Gore S, Zeidan A. Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial. Blood 2023, 142: 3252. DOI: 10.1182/blood-2023-182814.
- Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA)Kewan T, Bewersdorf J, Blaha O, Stahl M, Ali N, DeZern A, Sekeres M, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, Amaya M, Zeidner J, Savona M, Stempel J, Chandhok N, Logothetis C, Ramaswamy R, Rose A, Roboz G, Rolles B, Wang E, Harris A, Shallis R, Xie Z, Padron E, Maciejewski J, Sallman D, Della Porta M, Komrokji R, Zeidan A. Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Were Treated with Hypomethylating Agents (HMA). Blood 2023, 142: 3240. DOI: 10.1182/blood-2023-186340.
- Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective AnalysisBewersdorf J, Kewan T, Blaha O, Stahl M, Ali N, DeZern A, Sekeres M, Uy G, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, McMahon C, Zeidner J, Savona M, Stempel J, Chandhok N, Ramaswamy R, Roboz G, Rolles B, Wang E, Harris A, Amaya M, Hawkins H, Grenet J, Gurnari C, Shallis R, Xie Z, Maciejewski J, Sallman D, Della Porta M, Komrokji R, Zeidan A. Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis. Blood 2023, 142: 4613. DOI: 10.1182/blood-2023-178728.
- Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT)Kewan T, Bewersdorf J, Blaha O, Stahl M, Ali N, DeZern A, Sekeres M, Uy G, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, Amaya M, Zeidner J, Savona M, Stempel J, Chandhok N, Logothetis C, Cochran H, Rose A, Roboz G, Wang E, Rolles B, Harris A, Shallis R, Xie Z, Padron E, Maciejewski J, Sallman D, Della Porta M, Komrokji R, Zeidan A. Validation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Who Underwent Allogenic Stem Cell Transplantation (HSCT). Blood 2023, 142: 4980. DOI: 10.1182/blood-2023-186578.
- Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular DataKewan T, Bewersdorf J, Blaha O, Stahl M, Ali N, DeZern A, Sekeres M, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, Amaya M, Zeidner J, Savona M, Stempel J, Chandhok N, Logothetis C, Cochran H, Singh A, Roboz G, Rolles B, Wang E, Harris A, Shallis R, Xie Z, Padron E, Sallman D, Maciejewski J, Della Porta M, Komrokji R, Zeidan A. Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) with Missing Molecular Data. Blood 2023, 142: 4607. DOI: 10.1182/blood-2023-187053.
- Validation of the Composite Complete Response (cCR) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) - a Large, Multicenter, Retrospective Analysis from the Validate DatabaseBewersdorf J, Kewan T, Blaha O, Stahl M, Ali N, DeZern A, Sekeres M, Uy G, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, McMahon C, Zeidner J, Savona M, Stempel J, Chandhok N, Logothetis C, Roboz G, Rolles B, Wang E, Harris A, Amaya M, Hawkins H, Grenet J, Shallis R, Xie Z, Maciejewski J, Sallman D, Della Porta M, Komrokji R, Zeidan A. Validation of the Composite Complete Response (cCR) Definitions in the International Working Group (IWG) 2023 Criteria in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Treated with Hypomethylating Agents (HMA) - a Large, Multicenter, Retrospective Analysis from the Validate Database. Blood 2023, 142: 324. DOI: 10.1182/blood-2023-180299.
- Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate DatabaseKewan T, Bewersdorf J, Blaha O, Stahl M, Ali N, DeZern A, Sekeres M, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, Amaya M, Zeidner J, Savona M, Stempel J, Chandhok N, Cochran H, Ramaswamy R, Singh A, Roboz G, Rolles B, Wang E, Harris A, Shallis R, Xie Z, Padron E, Maciejewski J, Della Porta M, Komrokji R, Sallman D, Zeidan A. Clinical Implications of TP53 Mutations/Allelic State in Patients (Pts) with Myelodysplastic Syndromes/Neoplasms (MDS) Treated with Hypomethylating Agents (HMA)- a Multicenter, Retrospective Analysis from the Validate Database. Blood 2023, 142: 1002. DOI: 10.1182/blood-2023-186875.
- ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast CancerLi Z, Belitzky E, Blaha O, Cavaliere A, Katz S, Aboian M, Melegari L, Rajabimoghadam K, Kurpiewski S, Zhu X, Marquez-Nostra B. ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer. Cancers 2023, 15: 1589. PMID: 36900378, PMCID: PMC10001369, DOI: 10.3390/cancers15051589.
- Taking a chance: How likely am I to receive my preferred treatment in a clinical trial?Walter S, Blaha O, Esserman D. Taking a chance: How likely am I to receive my preferred treatment in a clinical trial? Statistical Methods In Medical Research 2023, 32: 572-592. PMID: 36628522, PMCID: PMC9983058, DOI: 10.1177/09622802221146305.
- Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomasLy C, Blaha O, Wei W, Galan A, Kluger H, Ariyan S, Olino K, Clune J. Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas. Frontiers In Oncology 2023, 12: 1077226. PMID: 36686728, PMCID: PMC9853390, DOI: 10.3389/fonc.2022.1077226.
- Simulating time-to-event data subject to competing risks and clustering: A review and synthesisMeng C, Esserman D, Li F, Zhao Y, Blaha O, Lu W, Wang Y, Peduzzi P, Greene E. Simulating time-to-event data subject to competing risks and clustering: A review and synthesis. Statistical Methods In Medical Research 2022, 32: 305-333. PMID: 36412111, DOI: 10.1177/09622802221136067.
- Regression methods for the appearances of extremes in climate dataYu C, Blaha O, Kane M, Wei W, Esserman D, Zelterman D. Regression methods for the appearances of extremes in climate data. Environmetrics 2022, 33 DOI: 10.1002/env.2764.
- Design and analysis of cluster randomized trials with time‐to‐event outcomes under the additive hazards mixed modelBlaha O, Esserman D, Li F. Design and analysis of cluster randomized trials with time‐to‐event outcomes under the additive hazards mixed model. Statistics In Medicine 2022, 41: 4860-4885. PMID: 35908796, PMCID: PMC9588628, DOI: 10.1002/sim.9541.
- Bayesian local exchangeability design for phase II basket trialsLiu Y, Kane M, Esserman D, Blaha O, Zelterman D, Wei W. Bayesian local exchangeability design for phase II basket trials. Statistics In Medicine 2022, 41: 4367-4384. PMID: 35777367, PMCID: PMC10279458, DOI: 10.1002/sim.9514.
- Effects of hypnosis versus enhanced standard of care on postoperative opioid use after total knee arthroplasty: the HYPNO-TKA randomized clinical trialMarkovits J, Blaha O, Zhao E, Spiegel D. Effects of hypnosis versus enhanced standard of care on postoperative opioid use after total knee arthroplasty: the HYPNO-TKA randomized clinical trial. Regional Anesthesia & Pain Medicine 2022, 47: 534-540. PMID: 35715013, DOI: 10.1136/rapm-2022-103493.
- Design and analysis of partially randomized preference trials with propensity score stratificationWang Y, Li F, Blaha O, Meng C, Esserman D. Design and analysis of partially randomized preference trials with propensity score stratification. Statistical Methods In Medical Research 2022, 31: 1515-1537. PMID: 35469503, PMCID: PMC10530658, DOI: 10.1177/09622802221095673.
- A comparison of analytical strategies for cluster randomized trials with survival outcomes in the presence of competing risksLi F, Lu W, Wang Y, Pan Z, Greene EJ, Meng G, Meng C, Blaha O, Zhao Y, Peduzzi P, Esserman D. A comparison of analytical strategies for cluster randomized trials with survival outcomes in the presence of competing risks. Statistical Methods In Medical Research 2022, 31: 1224-1241. PMID: 35290139, PMCID: PMC10518064, DOI: 10.1177/09622802221085080.
- Sample size calculation in hierarchical 2×2 factorial trials with unequal cluster sizesTian Z, Esserman D, Tong G, Blaha O, Dziura J, Peduzzi P, Li F. Sample size calculation in hierarchical 2×2 factorial trials with unequal cluster sizes. Statistics In Medicine 2022, 41: 645-664. PMID: 34978097, PMCID: PMC8962918, DOI: 10.1002/sim.9284.
- Attention-Deficit/Hyperactivity Disorder in 2- to 5-Year-Olds: A Primary Care Network Experience.Bannett Y, Feldman HM, Gardner RM, Blaha O, Huffman LC. Attention-Deficit/Hyperactivity Disorder in 2- to 5-Year-Olds: A Primary Care Network Experience. Academic Pediatrics 2021, 21: 280-287. PMID: 32360494, DOI: 10.1016/j.acap.2020.04.009.
- Handheld Ultrasound Device Usage and Image Acquisition Ability Among Internal Medicine Trainees: A Randomized Trial.Buesing J, Weng Y, Kugler J, Wang L, Blaha O, Hom J, Ahuja N, Kumar A. Handheld Ultrasound Device Usage and Image Acquisition Ability Among Internal Medicine Trainees: A Randomized Trial. Journal Of Graduate Medical Education 2021, 13: 76-82. PMID: 33680304, PMCID: PMC7901629, DOI: 10.4300/JGME-D-20-00355.1.
- Deep learning assistance for the histopathologic diagnosis of Helicobacter pyloriZhou S, Marklund H, Blaha O, Desai M, Martin B, Bingham D, Berry G, Gomulia E, Ng A, Shen J. Deep learning assistance for the histopathologic diagnosis of Helicobacter pylori. Intelligence-Based Medicine 2020, 1: 100004. DOI: 10.1016/j.ibmed.2020.100004.
- Deep learning assistance for the histopathologic diagnosis of Helicobacter pyloriZhou S, Marklund H, Blaha O, Desai M, Martin B, Bingham D, Berry GJ, Gomulia E, Ng AY, Shen J. Intelligence-Based Medicine; Vol 1–2, DOI:10.1016/j.ibmed.2020.100004, November 2020
- Social marketing for a farmer's market in an underserved community: A needs assessment.Skizim M, Sothern M, Blaha O, Tseng TS, Griffiths L, Joseph J, Nuss H. Social marketing for a farmer's market in an underserved community: A needs assessment. Journal Of Public Health Research 2017, 6: 815. PMID: 29441329, PMCID: PMC5806034, DOI: 10.4081/jphr.2017.815.
- Integrative Family Medicine - Are Louisiana Patients Ready?Dancisak B, Magonet G, Blaha O, Nuss HJ. Integrative Family Medicine - Are Louisiana Patients Ready? J La State Med Soc 2016, 168: 90-4. PMID: 27389376.